NCT03879837View on ClinicalTrials.gov

Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg

PHASE3CompletedINTERVENTIONAL
Enrollment

1,902

Participants

Timeline

Start Date

March 25, 2019

Primary Completion Date

May 28, 2021

Study Completion Date

July 9, 2021

Conditions
Asthma
Interventions
DRUG

Fluticasone propionate pressurized metered dose inhaler

110 mcg per actuation

DRUG

Flovent HFA pressurized metered dose inhaler

110 mcg per actuation

DRUG

Placebo pressurized metered dose inhaler

no active content

Trial Locations (1)

29303

Site 1, Spartanburg

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

Actavis Inc.

INDUSTRY

NCT03879837 - Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg | Biotech Hunter | Biotech Hunter